Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin

Epilepsia
J T BackmanP J Neuvonen

Abstract

Midazolam is a short-acting benzodiazepine which is used as an oral hypnotic agent in several countries. We studied the pharmacokinetic and pharmacodynamic aspects of an oral 15-mg dose of midazolam in 6 patients with epilepsy who are also taking carbamazepine (CBZ) or phenytoin (PHT). We compared results with those obtained in 7 noninduced control subjects. Plasma concentrations and effects of midazolam were measured for 10 h. In patients with epilepsy, the area under the plasma concentration-time curve (AUC) of midazolam (mean +/- SEM) was only 5.7% (0.60 +/- 0.16 vs. 10.5 +/- 0.6 microgram x min/ml), and the peak midazolam concentration was 7.4% (5.2 +/- 1.2 vs. 70.4 +/- 9.0 ng/ml) of its value in control subjects (p < 0.001). The elimination half-life (t l/2) of midazolam was 1.3 +/- 0.2 h in patients and 3.1 +/- 0.1 h in controls (p < 0.001). The low plasma midazolam concentrations in the patient group were associated with reduced pharmacodynamic effects as compared with control subjects [e.g., the Critical Flicker Fusion Test (CFFT), p < 0.05]. Induction of CYP3A (cytochrome P-450IIIA) enzymes by CBZ and PHT is the most likely explanation of the great difference in the pharmacokinetic and pharmacodynamic profiles of oral ...Continue Reading

References

Nov 1, 1992·The Journal of Clinical Investigation·J C KolarsP B Watkins
Jan 1, 1992·Epilepsia·M J Brodie
Jan 1, 1990·Clinical Pharmacokinetics·R L NationR W Milne
Jul 18, 1970·British Medical Journal·J G Hannington-Kiff
Nov 1, 1981·Clinical Pharmacology and Therapeutics·H AllonenU Klotz
Sep 1, 1984·British Journal of Clinical Pharmacology·E PeruccaA Richens
Dec 1, 1984·British Journal of Clinical Pharmacology·D J FreemanS G Carruthers
Jan 1, 1982·Clinical Pharmacokinetics·E Perucca
Oct 1, 1982·Journal of Pharmacokinetics and Biopharmaceutics·K K Chan, M Gibaldi
May 1, 1994·Clinical Pharmacology and Therapeutics·K T OlkkolaP J Neuvonen
Mar 1, 1994·British Journal of Clinical Pharmacology·J T BackmanP J Neuvonen
Mar 1, 1993·Clinical Pharmacology and Therapeutics·K T OlkkolaP J Neuvonen

❮ Previous
Next ❯

Citations

Nov 2, 2005·European Journal of Clinical Pharmacology·T FukasawaK Otani
Mar 19, 2005·European Journal of Clinical Pharmacology·S KondoK Otani
Jan 13, 1999·Pediatric Clinics of North America·A P Ten EickM D Reed
Sep 1, 1997·Journal of Clinical Anesthesia·J G Bovill
Feb 27, 1999·Journal of Clinical Pharmacy and Therapeutics·E Tanaka
Apr 16, 2002·Epilepsia·Philip N PatsalosClementina M van Rijn
May 23, 1998·Annual Review of Pharmacology and Toxicology·K E Thummel, G R Wilkinson
Oct 22, 2008·Nutrition & Metabolism·Zakia Bibi
Jul 29, 2003·Clinical Pharmacokinetics·Mikko NiemiKari T Kivistö
May 20, 2003·CNS Drugs·Leah M HesseDavid J Greenblatt
Jan 9, 2014·Clinical Drug Investigation·Sven WindPeter Stopfer
Jun 8, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Aleksandra Kotlinska-Lemieszek
May 13, 1998·British Journal of Clinical Pharmacology·T S LambergP J Neuvonen
Oct 16, 1999·Therapeutic Drug Monitoring·M NakajimaY Kuroiwa
Jun 17, 2006·Therapeutic Drug Monitoring·Yukihiro UjiieKoichi Otani
Oct 20, 2010·Expert Opinion on Drug Metabolism & Toxicology·Odette A Fahmi, Sharon L Ripp
May 1, 2010·Expert Opinion on Drug Discovery·Masashi HonmaHiroshi Suzuki
Feb 28, 2008·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Tuire TirkkonenKari Laine
Jan 19, 2008·Periodontology 2000·Elliot V Hersh, Paul A Moore
Feb 22, 2012·Basic & Clinical Pharmacology & Toxicology·Pertti J Neuvonen
Dec 3, 2014·Journal of Pain and Symptom Management·Robert TwycrossAndrew Wilcock
Feb 14, 2014·Drug Metabolism and Pharmacokinetics·Linda Björkhem-BergmanUlf Diczfalusy
Jan 1, 1997·Clinical Pharmacology and Therapeutics·K VillikkaP J Neuvonen
Jan 20, 1998·Clinical Pharmacology and Therapeutics·K VillikkaP J Neuvonen
Jan 1, 1999·Clinical Pharmacology and Therapeutics·K T KivistöP J Neuvonen
May 21, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Odette A FahmiDavid Nettleton
Jun 14, 2014·Drug Metabolism and Disposition : the Biological Fate of Chemicals·J George ZhangDavid M Stresser
Oct 24, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Kajsa P Kanebratt, Tommy B Andersson
May 16, 2013·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Linda Björkhem-BergmanUlf Diczfalusy
Jan 28, 2005·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Cuyue TangAnthony Y H Lu
Jul 14, 2006·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Sharon L RippSonia M de Morais

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
H FurukoriK Sugawara
Journal of Clinical Psychopharmacology
E H Rosen
© 2021 Meta ULC. All rights reserved